The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
 
Taro Shibuki
No Relationships to Disclose
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Guardant Health AMEA; Merck
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Incyte; J-pharma; MSD; Mylan; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); JPH Clinical Development (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Masayuki Furukawa
Honoraria - Astellas Amgen BioPharama (Inst); AstraZeneca; Chugai Pharma; Chugai Pharma (Inst); Daiichi Sankyo; Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical; Ono Pharmaceutical (Inst); Otsuka (Inst); SERVIER; Servier (Inst); Taiho Oncology (Inst); Taiho Pharmaceutical; Yakult Australia (Inst); Yakult Pharmaceutical
 
Yasuyuki Kawamoto
Honoraria - AstraZeneca; Incyte; Lilly Japan; Merck; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Japan Agency for Medical Research and Development; Takeda
 
Shinji Itoh
No Relationships to Disclose
 
Kumiko Umemoto
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical
 
Kentaro Sudo
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Nobumasa Mizuno
Honoraria - AstraZeneca; Fujifilm; MSD; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); Incyte (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Seagen (Inst)
 
Akinori Asagi
No Relationships to Disclose
 
Naohiro Okano
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Satoshi Shimizu
Research Funding - AstraZeneca (Inst); Delta-Fly Pharma (Inst); IQvia (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
John H Strickler
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Inivata; Janssen Oncology; Lilly; Natera (Inst); Pfizer; Roche/Genentech; Seagen; Silverback Therapeutics; Taiho Oncology; Takeda; Viatris
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene; Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Leap Therapeutics (Inst); Lilly (Inst); Nektar (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Seagen
 
Takao Fujisawa
Honoraria - Merck Serono
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Genomedia (Inst); Molecular Health (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
Chigusa Morizane
Honoraria - AstraZeneca; Eisai; Incyte Japan; MSD K.K.; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; MSD K.K.; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo RD Novare; Eisai (Inst); Hitachi (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Chugai Pharma; Eisai; Guardant Health; Lilly Japan; MSD; Novartis; Roche; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)